After a slow start to the year, IPO activity for biotech companies picked up with 11 graduating to the public arena. However, the total amount raised was lower than the first quarter haul with most companies in the second quarter pricing their offerings within or below their ranges, and precious few transactions generated enough support to push above their original expectations reflecting the fact that the financial markets still remain volatile. Read More
With funding from the world's largest source of global health initiatives, the U.S., barely growing and global health development funding stagnant at around $36.4 billion annually, it has become increasingly clear to some that the time for creativity in funding public health programs is now. Read More
